Q2 2026 Medicure Inc Earnings Call Transcript
Key Points
- Total net revenue increased to $7.4 million in Q2 2026 from $6.7 million in Q2 2025, driven by growth in ZYPITAMAG and pharmacy acquisitions.
- ZYPITAMAG revenue through the traditional insurance channel rose to $850,000 from $751,000 year-over-year, reflecting higher formulary utilization.
- Marley Drug revenue grew to $3.4 million from $3.1 million, with ZYPITAMAG sales through this channel increasing to $1.3 million from $908,000.
- Adjusted EBITDA improved to $172,000 from a negative $28,000 in the prior year quarter, indicating better operational efficiency.
- The company has no debt on its books, providing financial stability for ongoing operations and R&D investments.
- Net loss widened to $1.4 million from $786,000 in Q2 2025, impacted by a $864,000 rebate liability from a CMS assessment.
- AGGRASTAT revenue declined significantly to $661,000 from $1.7 million due to increased competition from generic tirofiban hydrochloride.
- Cash balance decreased to $1.8 million from $3.8 million at the end of 2025, driven by working capital changes and acquisition payments.
- Selling expenses increased to $2.8 million from $2.1 million, partly due to the CMS rebate liability and the West Olympia acquisition.
- Research and development expenses, while lower, remain a significant cash outflow at $608,000, with no immediate revenue contribution from MC1.
Welcome to Medicure's earnings conference call for the quarter ended June 30, 2026. My name is Holly, and I will be your operator for today's call. (Operator Instructions)
Before we proceed, I would like to remind everyone that this presentation contains forward-looking statements relating to future results, events and expectations, which are made pursuant to the Safe Harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, those described in the company's most recent annual information form and Form 20-F. (Operator Instructions) Please note that this conference call is being recorded, and today's date is August 17, 2026.
I would now like to turn the conference call over to Dr. Albert Friesen, Chief Executive Officer of Medicure Inc. Please go ahead, Dr. Friesen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
